Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL.

ABSTRACT:

Background

For relapsing-remitting multiple sclerosis (RRMS), there is a need for biomarker development beyond clinical manifestations and MRI. Soluble neurofilament light chain (sNfL) has emerged as a biomarker for inflammatory activity in RRMS. However, there are limitations to the accuracy of sNfL in identifying relapses. Here, we sought to identify a panel of biomarkers that would increase the precision of distinguishing patients in relapse compared to sNfL alone.

Methods

We used a multiplex approach to measure levels of 724 blood proteins in two distinct RRMS cohorts. Multiple t-tests with covariate correction determined biomarkers that were differentially regulated in relapse and remission. Logistic regression models determined the accuracy of biomarkers to distinguish

SUBMITTER: Gawde S 

PROVIDER: S-EPMC9351348 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature